Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
- Interventions
- Biological: BI 836858 (BAML-16-001-S2)Drug: ZE46-0134 (BAML-16-001-S21)Other: Laboratory Biomarker AnalysisDrug: AG-221 (BAML-16-001-S3)Drug: AG-120 (BAML-16-001-S16)Drug: AZD5153 (BAML-16-001-S10)Drug: TP-0903 (BAML-16-001-S14)Drug: AZD5991 (BAML-16-001-S18)Drug: SNDX-5613 (BAML-16-001-S17)
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Beat AML, LLC
- Target Recruit Count
- 2000
- Registration Number
- NCT03013998
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath